To evaluate post-operative treatment results of serous endometrial carcinoma (SEC) comparing two histological subtypes (with and without an endometrioid component) and its impact on overall survival (OS), local control, distant relapses in patients treated from 2003-2014. Material and Methods: Thirty-four patients (p) with SEC were treated with post-operative radiotherapy at our centre. All the patients were divided into two groups according to the histological subtype: 21p with pure SEC in Group 1, 13p with mixed SEC with endometrioid cells in Group 2. All patients were staged using 2009-FIGO classification. Group 1: 10-IA, 5-IB, 1-IIIA, 4-IIIC1, 1-IIIC2. Group 2: 2-IA, 7-IB, 2-IIIA, 1-IIIB, 1-IIIC1. Pathology. Group 1: Grade (G): G2-in 5p, G-3 in 16p. Group 2: Grade: G1 in 1p, G2-in 3p, G-3 in 9 p. Myometrial invasion was presented in 10p in Group 1 and 3p in Group 2. Median tumour size was 3.6cm in Group 1 and 3.9cm in Group 2. Vascular and lymphatic space invasion was presented in 5p (23.8%) in Group 1 and in 6p (46.2%) in Group 2. Radiotherapy: all p received high-dose-rate brachytherapy (1-3 fractions of 4-7 Gy), and 17/21p in Group 1 and 12/13p in Group 2 received external beam irradiation (mean dose of 45.2Gy in Group 1 and 44.6 Gy in Group 2, after 3D planning and 4-field technique tailored to surgical results). Chemotherapy: 4-6 cycles of carboplatin + paclitaxel in 8/21 pts in Group 1 and 6/13 pts in Group 2.
Results: Mean age: 68.7 years (57-81) in Group 1, in Group 2. Mean follow-up (months): in Group 1: 57 (7.8-153), in Group 2: 63 (12-117.8). Relapses: No vaginal relapses were developed; only 3/34p (8.8%) presented locoregional relapse (2p in Group 1 and 1p in Group 2); 8/34 p (23.5%) had distant metastasis (3/21 in Group 1 and 5/13 in Group 2) and 13/34p (38.2%) had died at the time of the last control. The mean OS (months) was 58.9 (range 22.9-138.8) in Group 1 and 37.1 (range 12-84.8) in Group 2. The mean survival time to metastasis (months) was 38.4 (range 8.2-70.7) in Group 1 and 19.6 (range 9.5-53) in Group 2. The mean survival time to loco-regional relapse (months) was 27.5 (10.9-16.6) in Group 1 (2p) and 13 in Group 2 (only 1p).
Conclusion:
At the time of the last control 61.8%p were alive. The main cause of relapse was distant metastases followed by loco-regional relapse with no patient showing vaginal relapse. The mean OS was substantially longer in patients with the pure SEC subtype (58.9 vs. 37.1 months) as was the mean survival time to metastasis (38.4 vs. 19.6 months) possibly due to the higher number of IA stage patients. Comparisons of two histological subgroups are scarce in the literature. 
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